Drug Details
General Information of the Drug (ID: DR0221) | ||||
---|---|---|---|---|
Name |
2-deoxy-D-glucose
|
|||
Synonyms |
154-17-6; Deoxyglucose; 2-Desoxy-D-glucose; 2-DG; 2-Deoxy-D-arabinohexose; 2-Deoxy-D-mannose; D-2-Deoxyglucose; (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal; arabino-Hexose, 2-deoxy-; UNII-9G2MP84A8W; D-Arabino-hexose, 2-deoxy-; HSDB 5484; D-Glucose, 2-deoxy-; 9G2MP84A8W; 2 Deoxyglucose; 2 Deoxy D glucose; 2 Desoxy D glucose; D-arabino-2-desoxyhexose; 2-Desoxy-D-glucose [French]; CCRIS 9094; MFCD00151328; d-2-glucodesose; EINECS 205-823-0; D-2dGlc; BRN 1723331; deoxy-d-glucose, 2-; 2-DEOXYLGLUCOSE; SCHEMBL7670; 4-01-00-04282 (Beilstein Handbook Reference); CHEMBL2074932; DTXSID1037648; ALBB-022735; AMY10934; ZINC2512351; ANW-21488; CD0012; AKOS015919409; AKOS015924825; DB08831; LS30109; 2-Deoxy-D-glucose, BioXtra, >=98%; AS-12502; AB0012037; DB-024740; D0051; 54D176; D-arabino-Hexose, 2-deoxy- (6CI,8CI,9CI); S-1013; 2-Deoxy-D-glucose, >=98% (GC), crystalline; 2-Deoxy-D-glucose, >=99% (GC), crystalline; Q3266534; 5CFA0332-FB70-485D-A064-6C4C39E7CBA1; 2-Deoxy-D-glucose, United States Pharmacopeia (USP) Reference Standard
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C6H12O5
|
|||
PubChem CID | ||||
Canonical SMILES |
C(C=O)C(C(C(CO)O)O)O
|
|||
InChI |
1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1
|
|||
CAS Number |
CAS 154-17-6
|
|||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | MEK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | PRKAA2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | STK11 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | |||
THP-1 | CVCL_0006 | Childhood acute monocytic leukemia | Homo sapiens | |||
Experimental
Result(s) |
2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: Involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/ AMPK signaling pathways. | |||||
Metformin | Galega officinalis | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | VOA1056 | CVCL_V536 | Adenocarcinoma | Homo sapiens | ||
VOA1312 | CVCL_V538 | Adenocarcinoma | Homo sapiens | |||
VOA5646 | CVCL_VQ39 | Adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
2-DG significantly inhibited glycolysis in all LGSOC lines and combination with metformin showed synergistic inhibitory effect. | |||||
Tephrosin | Tephrosia vogelii | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
The combination of TSN and 2-DG increased the sensitivity of cancer cells to 2-DG. |